Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
523 Leser
Artikel bewerten:
(2)

Osteotec Signs Exclusive Distribution Agreement with icotec ag to advance Spine Tumour Therapy in Great Britain

NEWBURY, England, May 9, 2025 /PRNewswire/ -- Osteotec, the market leading manufacturer and distributor of specialised medical devices, is pleased to announce an exclusive distribution agreement with icotec, the world leader of non-metallic spinal implants optimized for spine tumour therapy.

Osteotec_Logo

This collaboration, effective from May 8, marks a key milestone in Osteotec's strategic growth, further expanding its spine product portfolio to provide physicians in Great Britain with advanced solutions that support improved patient outcomes.

Headquartered in Altstätten, Switzerland, icotec develops and manufactures innovative, radiolucent implants derived from BlackArmor® Carbon/PEEK material for the operative treatment of tumour diseases of the spine and other indications.

icotec's BlackArmor® Carbon/PEEK material provides value in radiotherapy, enabling artifact-free CT/MRI images for accurate delineation of critical structures and accelerated dose planning, helping physicians improve diagnostic accuracy and deliver more effective treatment options for patients suffering with primary and metastatic spinal tumours.

"This partnership with icotec represents a significant step forward in our commitment to supporting physicians with innovative spinal solutions," said Dean Stockwell, Osteotec Sales and Marketing Director.

"icotec's innovative approach to the treatment of spinal oncology aligns with our mission to improve surgical outcomes and patient care. By adding icotec's BlackArmor® implants to our growing spine portfolio, we are broadening the range of advanced tools available to physicians, enabling them to address the unique challenges associated with treating spinal tumours and other indications."

The agreement solidifies Osteotec's role as a supplier of spinal solutions in Great Britain, building on its established presence and expertise in supporting both NHS and private healthcare providers.

"We are excited to partner with Osteotec, a company renowned for its deep-rooted connections within the spine community and its dedication to improving patient care," said Kurt Zoller, Chief Marketing Officer at icotec.

"Through this collaboration, we aim to make our BlackArmor® Carbon/PEEK implants more accessible to physicians across Great Britain, empowering them to deliver enhanced treatment options for patients with complex spinal conditions."

About Osteotec

Osteotec is a manufacturer and distributor of medical devices headquartered in Newbury, UK, with offices in Dublin and Malmö. Established in 1993, Osteotec has been supplying into the NHS and private healthcare sectors for the past 31 years.

Osteotec manufactures and distributes the Osteotec Silicone Finger, ChiroKlip and the Concentric Bone Graft System and is a distributor for world-leading orthopaedic partners including Highridge Medical, SI-BONE, TriMed, Enovis and Cerapedics.

Media Contact:
Harriet Bawden
Marketing Manager
mkt@osteotec.com | 020 3011 5574
For more information, visit - www.osteotec.com

About icotec

icotec is the leading company for the treatment of spinal tumours and other indications with a new generation of high-tech implants. With its BlackArmor® Carbon/PEEK implants, icotec combines cutting-edge technologies and industry expertise to deliver innovative and reliable solutions for spine surgeons and their patients and is dedicated to advancing the field of spinal implantation.

With a track record of clinical success and a commitment to continuous innovation, icotec is poised to shape the future of spinal surgery. The comprehensive product portfolio has received FDA and CE clearance and is supported by numerous Key Opinion Leaders and spine surgery centres worldwide.

Media Contact:

John Clough
Vice President of Product Management and New Indications
John.clough@icotec-medical.com
For more information, visit www.icotec-medical.com

Logo - https://mma.prnewswire.com/media/2151731/5310260/Osteotec_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/osteotec-signs-exclusive-distribution-agreement-with-icotec-ag-to-advance-spine-tumour-therapy-in-great-britain-302451009.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.